There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (NASDAQ:ZYNE) and KemPharm (NASDAQ:KMPH) with bullish sentiments.
Zynerba Pharmaceuticals (ZYNE)
Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Zynerba Pharmaceuticals yesterday and set a price target of $18. The company’s shares opened today at $10.11.
According to TipRanks.com, Lee is a 3-star analyst with an average return of 2.0% and a 44.2% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Karyopharm Therapeutics, and Aquinox Pharmaceuticals.
Zynerba Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.33, implying a 101.1% upside from current levels. In a report issued on July 5, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
KemPharm (KMPH)
Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on KemPharm yesterday and set a price target of $11. The company’s shares opened today at $6.
Steadman said:
“We maintain our BUY rating on KMPH shares given what we see as a potentially positive product profile for KP415 once all the data kinks are worked out. We’d be buyers on any KMPH weakness on this data read.”
According to TipRanks.com, Steadman is a 4-star analyst with an average return of 7.9% and a 54.7% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Perrigo Company plc.
KemPharm has an analyst consensus of Strong Buy, with a price target consensus of $13.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
